VBI Vaccines (NASDAQ:VBIV) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a report released on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Down 19.0 %

VBIV stock opened at $0.09 on Wednesday. The business has a 50 day moving average of $0.60 and a 200-day moving average of $0.61. VBI Vaccines has a 12-month low of $0.08 and a 12-month high of $1.35.

VBI Vaccines (NASDAQ:VBIV) last released its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.02). The business had revenue of $1.21 million during the quarter, compared to the consensus estimate of $2.85 million. VBI Vaccines had a negative net margin of 881.79% and a negative return on equity of 525.42%.

About VBI Vaccines

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.